Helper roles of NK and CD8+ T cells in the induction of tumor immunity: Polarized dendritic cells as cancer vaccines

Pawel Kalinski, Yutaro Nakamura, Payal Watchmaker, Adam Giermasz, Ravikumar Muthuswamy, Robbie B. Mailliard

Research output: Contribution to journalReview article

54 Citations (Scopus)

Abstract

The work in our laboratory addresses two interrelated areas of dendritic cell (DC) biology: (1) the role of DCs as mediators of feedback interactions between NK cells, CD8+ and CD4+ T cells; and (2) the possibility to use such feedback and the paradigms derived from anti-viral responses, to promote the induction of therapeutic immunity against cancer. We observed that CD8+ T cells and NK cells, the classical "effector" cells, also play "helper" roles, regulating ability of DCs to induce type-1 immune immunity, critical for fighting tumors and intracellular pathogens. Our work aims to delineate which pathways of NK and CD8+ T cell activation result in their helper activity, and to identify the molecular mechanisms allowing them to induce type-1 polarized DCs (DC1s) with selectively enhanced ability to promote type-1 responses and anti-cancer immunity. The results of these studies allowed us and our colleagues to design phase I/II clinical trials incorporating the paradigms of DC polarization and helper activity of effector cells in cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)137-146
Number of pages10
JournalImmunologic Research
Volume36
Issue number1-3
StatePublished - Sep 2006

Fingerprint

Cancer Vaccines
Dendritic Cells
Immunity
T-Lymphocytes
Natural Killer Cells
Neoplasms
Phase II Clinical Trials
Clinical Trials, Phase I
Immunotherapy
Cell Biology
Therapeutics

Keywords

  • Cancer
  • Clinical trials
  • Colorectal cancer
  • CTL
  • Dendric cells
  • Immunotherapy
  • Melanoma
  • NK cells
  • Prostate cancer
  • Th1
  • Vaccines

ASJC Scopus subject areas

  • Immunology

Cite this

Kalinski, P., Nakamura, Y., Watchmaker, P., Giermasz, A., Muthuswamy, R., & Mailliard, R. B. (2006). Helper roles of NK and CD8+ T cells in the induction of tumor immunity: Polarized dendritic cells as cancer vaccines. Immunologic Research, 36(1-3), 137-146.

Helper roles of NK and CD8+ T cells in the induction of tumor immunity : Polarized dendritic cells as cancer vaccines. / Kalinski, Pawel; Nakamura, Yutaro; Watchmaker, Payal; Giermasz, Adam; Muthuswamy, Ravikumar; Mailliard, Robbie B.

In: Immunologic Research, Vol. 36, No. 1-3, 09.2006, p. 137-146.

Research output: Contribution to journalReview article

Kalinski, P, Nakamura, Y, Watchmaker, P, Giermasz, A, Muthuswamy, R & Mailliard, RB 2006, 'Helper roles of NK and CD8+ T cells in the induction of tumor immunity: Polarized dendritic cells as cancer vaccines', Immunologic Research, vol. 36, no. 1-3, pp. 137-146.
Kalinski, Pawel ; Nakamura, Yutaro ; Watchmaker, Payal ; Giermasz, Adam ; Muthuswamy, Ravikumar ; Mailliard, Robbie B. / Helper roles of NK and CD8+ T cells in the induction of tumor immunity : Polarized dendritic cells as cancer vaccines. In: Immunologic Research. 2006 ; Vol. 36, No. 1-3. pp. 137-146.
@article{fb05abccc4e548b29f739dd57f880810,
title = "Helper roles of NK and CD8+ T cells in the induction of tumor immunity: Polarized dendritic cells as cancer vaccines",
abstract = "The work in our laboratory addresses two interrelated areas of dendritic cell (DC) biology: (1) the role of DCs as mediators of feedback interactions between NK cells, CD8+ and CD4+ T cells; and (2) the possibility to use such feedback and the paradigms derived from anti-viral responses, to promote the induction of therapeutic immunity against cancer. We observed that CD8+ T cells and NK cells, the classical {"}effector{"} cells, also play {"}helper{"} roles, regulating ability of DCs to induce type-1 immune immunity, critical for fighting tumors and intracellular pathogens. Our work aims to delineate which pathways of NK and CD8+ T cell activation result in their helper activity, and to identify the molecular mechanisms allowing them to induce type-1 polarized DCs (DC1s) with selectively enhanced ability to promote type-1 responses and anti-cancer immunity. The results of these studies allowed us and our colleagues to design phase I/II clinical trials incorporating the paradigms of DC polarization and helper activity of effector cells in cancer immunotherapy.",
keywords = "Cancer, Clinical trials, Colorectal cancer, CTL, Dendric cells, Immunotherapy, Melanoma, NK cells, Prostate cancer, Th1, Vaccines",
author = "Pawel Kalinski and Yutaro Nakamura and Payal Watchmaker and Adam Giermasz and Ravikumar Muthuswamy and Mailliard, {Robbie B.}",
year = "2006",
month = "9",
language = "English (US)",
volume = "36",
pages = "137--146",
journal = "Immunologic Research",
issn = "0257-277X",
publisher = "Humana Press",
number = "1-3",

}

TY - JOUR

T1 - Helper roles of NK and CD8+ T cells in the induction of tumor immunity

T2 - Polarized dendritic cells as cancer vaccines

AU - Kalinski, Pawel

AU - Nakamura, Yutaro

AU - Watchmaker, Payal

AU - Giermasz, Adam

AU - Muthuswamy, Ravikumar

AU - Mailliard, Robbie B.

PY - 2006/9

Y1 - 2006/9

N2 - The work in our laboratory addresses two interrelated areas of dendritic cell (DC) biology: (1) the role of DCs as mediators of feedback interactions between NK cells, CD8+ and CD4+ T cells; and (2) the possibility to use such feedback and the paradigms derived from anti-viral responses, to promote the induction of therapeutic immunity against cancer. We observed that CD8+ T cells and NK cells, the classical "effector" cells, also play "helper" roles, regulating ability of DCs to induce type-1 immune immunity, critical for fighting tumors and intracellular pathogens. Our work aims to delineate which pathways of NK and CD8+ T cell activation result in their helper activity, and to identify the molecular mechanisms allowing them to induce type-1 polarized DCs (DC1s) with selectively enhanced ability to promote type-1 responses and anti-cancer immunity. The results of these studies allowed us and our colleagues to design phase I/II clinical trials incorporating the paradigms of DC polarization and helper activity of effector cells in cancer immunotherapy.

AB - The work in our laboratory addresses two interrelated areas of dendritic cell (DC) biology: (1) the role of DCs as mediators of feedback interactions between NK cells, CD8+ and CD4+ T cells; and (2) the possibility to use such feedback and the paradigms derived from anti-viral responses, to promote the induction of therapeutic immunity against cancer. We observed that CD8+ T cells and NK cells, the classical "effector" cells, also play "helper" roles, regulating ability of DCs to induce type-1 immune immunity, critical for fighting tumors and intracellular pathogens. Our work aims to delineate which pathways of NK and CD8+ T cell activation result in their helper activity, and to identify the molecular mechanisms allowing them to induce type-1 polarized DCs (DC1s) with selectively enhanced ability to promote type-1 responses and anti-cancer immunity. The results of these studies allowed us and our colleagues to design phase I/II clinical trials incorporating the paradigms of DC polarization and helper activity of effector cells in cancer immunotherapy.

KW - Cancer

KW - Clinical trials

KW - Colorectal cancer

KW - CTL

KW - Dendric cells

KW - Immunotherapy

KW - Melanoma

KW - NK cells

KW - Prostate cancer

KW - Th1

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=33947111517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947111517&partnerID=8YFLogxK

M3 - Review article

C2 - 17337774

AN - SCOPUS:33947111517

VL - 36

SP - 137

EP - 146

JO - Immunologic Research

JF - Immunologic Research

SN - 0257-277X

IS - 1-3

ER -